Mary Haak-Frendscho, PhD

ceo, Blueline Bioscience

Mary Haak-Frendscho is CEO and member of the Board of Directors of Blueline Bioscience, and a Venture Partner with Versant Ventures. Dr. Haak-Frendscho also serves on the Board of Directors at Northern Biologics and as Executive Chair of Sirenas.

Mary brings 25 years of biotechnology industry experience spanning global pharma to early stage biotech start-ups. Prior to joining Blueline, she established and was Chairman of the Board of Compugen, Inc. and was CEO and member of the Board at Igenica Biotherapeutics, Inc. Previously Mary was founding President, CSO and Board member of Takeda San Francisco, establishing and overseeing Takeda’s Center of Excellence for Biologics. Earlier in her career Dr. Haak-Frendscho held positions of increasing responsibility at XOMA, Abgenix (now Amgen), and Genentech, where she secured collaborative relationships with external corporate partners and led therapeutic programs. At Genentech, she played a key role in the development of omalizumab (Xolair®).

An immunologist by training, Mary obtained her BS from the University of Michigan, MLA from Washington University in St. Louis, MS from SUNY-Stony Brook, CSEP from Columbia University Graduate School of Business and PhD from the University of Wisconsin, where she has an adjunct appointment in the Department of Pathobiological Sciences.


Brad Bolzon, PHD

Director, Blueline Bioscience

Brad Bolzon is a Director of Blueline Bioscience and a Managing Director with Versant Ventures.

Brad brings more than thirteen years of global pharmaceutical industry experience to Versant’s biotech investment team. He specializes in early-stage biotech investing with a particular emphasis on new company start-ups.

Prior to joining Versant, Brad served as Executive Vice President, Global Head of Business Development, Licensing & Alliances with F. Hoffmann-La Roche. Under his leadership, Roche established alliances with over 75 biotech companies worldwide and significantly strengthened its product pipeline. Previously, Brad held executive roles at Eli Lilly in drug discovery, clinical research, regulatory affairs, and business development.

Jerel Davis, phd

Director, Blueline Bioscience

Jerel Davis is a Director of Blueline Bioscience and an Investment Professional with Versant Ventures.

Jerel joined Versant from McKinsey & Company where he was an Associate Principal.  During his six years with McKinsey, he advised healthcare corporations in pharmaceuticals, biotechnology, medical device, and molecular diagnostics.  He has worked in a number of healthcare markets globally including the US, Europe, China, Russia, and India.  Jerel was a post doctoral researcher at Stanford University until 2005 and a researcher at Amgen from 1999-2000.

Jerel is currently a board observer at Inception and Quanticel.

Jerel received a PhD in Biological Sciences from Stanford University where he studied Genomics and Population Genetics.  Jerel earned a BS in Biology and Mathematics from Pepperdine University.

Gianni Gromo, md, phd

Director, Blueline Bioscience

Gianni is a Director of Blueline Bioscience and a Venture Partner with Versant Ventures.

Gianni previously served as a Senior Executive with several pharmaceutical companies, most recently Hoffmann-La Roche, where  he successfully lead research and development teams.  Gianni’s roles at Roche included Research Head of Global Cardiovascular and Metabolic Research, where he was responsible for all discovery and development activities in the CV, Renal and Metabolic areas; Head of Discovery Research, Basel Site; Global Head of the Metabolic and Vascular Disease Business Unit; and more recently Head of  the Roche China R&D center, Shanghai.  Prior to Roche, Gianni was Assistant Professor (tenure track), Immunobiology Research Center, Department of Laboratory Medicine and Pathology, University of Minnesota, Minneapolis, Minnesota, USA; Research Director at Italfarmaco SpA, Milano, Italy; and Director of Biology-Cardiovascular-Lilly Research Laboratories, Indianapolis, Indiana, USA.

He served as a  Scientific Advisor to CSIRO (Australia), Baker Institute (Australia), Integra (Yissum/ Hebrew University, Israel)Momentum Fund (Ramot / Tel Aviv University).

He serves on the Board of Directors of Novira Therapeutics (USA), and Piqur (Switzerland).

Gianni received his MD and PhD in Clinical and Experimental Hematology at University of Milano, Italy.

Joel Drewry, phd

Associate, Blueline Bioscience

Joel Drewry is an Associate with Blueline Bioscience. 

During the first year of operation Dr. Drewry also served as a Strategy and Operations Associate at Northern Biologics, an antibody therapeutics startup financed by Versant and Celgene in 2014.

Prior to joining Blueline in 2014, Joel was an industrial post-doctoral fellow at the Centre for Probe Development and Commercialization. His research at the CPDC involved designing and developing a proprietary linker-payload platform that enables the efficient conversion of antibodies and other targeting vectors into radioimmunoconjugate therapeutics for oncology. The first radioimmunoconjugate developed at the CPDC completed phase I trials in 2014. 

Joel received a PhD in organic chemistry from the University of Toronto in 2012, where he studied medicinal chemistry and molecular recognition.

Stefan Larson, phd

Special Advisor, blueline bioscience

Stefan Larson serves as a special advisor to Blueline Bioscience.

Dr. Larson was the founding President of Blueline Bioscience and an Entrepreneur-in-Residence with Versant Ventures. Currently Dr. Larson is CEO of Northern Biologics, the first company launched by Blueline Bioscience.

Prior to joining Blueline, Dr. Larson was the co-founding CEO and Chair of Tornado Medical Systems, a revenue stage scientific and medical instruments company with several product lines in high performance Raman spectroscopy, hyperspectral imaging, and spectral domain optical coherence tomography (OCT). During his 3-year tenure as CEO, he was responsible for raising $16M of equity financing and closing commercial co-development and marketing partnerships with several of the largest global optical instruments OEMs. Dr. Larson began his professional career as a management consultant in the San Francisco and Toronto offices of McKinsey & Company, serving Fortune 500 clients in the healthcare and technology sectors as an Associate Principal in the firm.

A long-time advocate of Toronto’s biomedical cluster, Dr. Larson has served on many related private and public sector governance bodies, including the Governing Council and Business Board of the University of Toronto, the Board of Directors of the Ontario Bioscience Innovation Organization (OBIO), the Steering Committee of the Toronto Regional Board of Trade’s Health Science Cluster initiative, the Commercialization Review Committee of the Centre for Commercialization of Regenerative Medicine (CCRM), the MaRS Innovation PoP Grant Review Panel, and the Steering Committee for OBIO’s Capital Access Advisory Program. In 2010, he was a recipient of the Arbor Award for Exceptional Volunteer Service to the University of Toronto.

Dr. Larson received his Ph.D. in Biophysics from Stanford University, where he studied as a James H. Clark Graduate Fellow.